Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 235.54 USD 0.06%
Market Cap: 32.5B USD

Intrinsic Value

The intrinsic value of one NTRA stock under the Base Case scenario is 93.66 USD. Compared to the current market price of 235.54 USD, Natera Inc is Overvalued by 60%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NTRA Intrinsic Value
93.66 USD
Overvaluation 60%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Natera Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about NTRA?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NTRA valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Natera Inc.

Explain Valuation
Compare NTRA to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Natera’s heavy reliance on insurance reimbursement for its genetic tests exposes it to pricing pressures and policy shifts, potentially squeezing margins and constraining revenue growth if reimbursement rates decline.

Investor expectations for rapid pipeline expansion may not materialize if its research efforts in organ transplant rejection monitoring or oncology are slow to show clinical or financial results, raising concerns over R&D return on investment.

The competitive landscape in cell-free DNA testing is intensifying, and larger diagnostic rivals with established distribution channels could undercut Natera’s share in both prenatal and oncology markets.

Bull Theses

Natera’s strong foothold in the noninvasive prenatal testing (NIPT) market, underpinned by robust clinical data and brand recognition, positions it to capture a growing share of the women’s health sector.

Strategic expansion into oncology with Signatera and into transplant care with Prospera capitalizes on emerging, high-growth testing categories, potentially driving a diverse revenue mix and boosting margins long term.

A steady focus on proprietary cell-free DNA technology and collaborations with leading healthcare providers enhances competitive differentiation, offering a scalable platform to add new therapies and tests to its pipeline.

Show More Less
How do you feel about NTRA?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Natera Inc

Current Assets 1.4B
Cash & Short-Term Investments 1B
Receivables 286.4m
Other Current Assets 118.5m
Non-Current Assets 374.2m
PP&E 303.5m
Other Non-Current Assets 70.7m
Current Liabilities 442m
Accounts Payable 46.5m
Accrued Liabilities 283.3m
Short-Term Debt 80.3m
Other Current Liabilities 31.9m
Non-Current Liabilities 127.3m
Other Non-Current Liabilities 127.3m
Efficiency

Free Cash Flow Analysis
Natera Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Natera Inc

Revenue
2.1B USD
Cost of Revenue
-769.3m USD
Gross Profit
1.3B USD
Operating Expenses
-1.7B USD
Operating Income
-351.9m USD
Other Expenses
42.7m USD
Net Income
-309.2m USD
Fundamental Scores

NTRA Profitability Score
Profitability Due Diligence

Natera Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Natera Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

NTRA Solvency Score
Solvency Due Diligence

Natera Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Low D/E
Short-Term Solvency
71/100
Solvency
Score

Natera Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NTRA Price Targets Summary
Natera Inc

Wall Street analysts forecast NTRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTRA is 244.57 USD with a low forecast of 187.86 USD and a high forecast of 294 USD.

Lowest
Price Target
187.86 USD
20% Downside
Average
Price Target
244.57 USD
4% Upside
Highest
Price Target
294 USD
25% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Natera Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NTRA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

NTRA Insider Trading
Buy and sell transactions by insiders

NTRA News

Other Videos
What is the Intrinsic Value of one NTRA stock?

The intrinsic value of one NTRA stock under the Base Case scenario is 93.66 USD.

Is NTRA stock undervalued or overvalued?

Compared to the current market price of 235.54 USD, Natera Inc is Overvalued by 60%.

Back to Top